Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T, Jaccard A, Guellich A, Lavergne D, Galat A, Deux JF, Hittinger L, Dupuis J, Frenkel V, Rigaud C, Plante-Bordeneuve V, Bodez D, Mohty D. Damy T, et al. Among authors: lavergne d. Amyloid. 2016 Sep;23(3):194-202. doi: 10.1080/13506129.2016.1221815. Epub 2016 Sep 20. Amyloid. 2016. PMID: 27647161
Diagnostic score of cardiac involvement in AL amyloidosis.
Nicol M, Baudet M, Brun S, Harel S, Royer B, Vignon M, Lairez O, Lavergne D, Jaccard A, Attias D, Macron L, Gayat E, Cohen-Solal A, Arnulf B, Logeart D. Nicol M, et al. Among authors: lavergne d. Eur Heart J Cardiovasc Imaging. 2020 May 1;21(5):542-548. doi: 10.1093/ehjci/jez180. Eur Heart J Cardiovasc Imaging. 2020. PMID: 31292624
Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series.
Rech JS, Arnulf B, de Margerie-Mellon C, Talbot A, Malphettes M, Vignon M, Royer B, Lavergne D, Kambouchner M, Meignin V, Bergeron A, Prevot G, Brillet PY, Martinod E, Bridoux F, Nunes H, Jaccard A, Valeyre D, Uzunhan Y. Rech JS, et al. Among authors: lavergne d. Am J Hematol. 2019 Nov;94(11):1214-1226. doi: 10.1002/ajh.25608. Epub 2019 Aug 23. Am J Hematol. 2019. PMID: 31396978 Free article.
Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex.
Penot A, Abraham J, Debarri H, Desport E, Aguilar C, Lavergne D, Auroy F, Leleu X, Goldstein A, Kolb B, Bridoux F, Fermand JP, Leblond V, Jaccard A. Penot A, et al. Among authors: lavergne d. Amyloid. 2011 Jun;18 Suppl 1:145-7. doi: 10.3109/13506129.2011.574354054. Amyloid. 2011. PMID: 21838466 Clinical Trial. No abstract available.
Hepatocyte growth factor measurement in AL amyloidosis.
Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, Moreau S, Yagoubi F, Bordessoule D, Lavergne D, Bridoux F, Jaccard A. Abraham J, et al. Among authors: lavergne d. Amyloid. 2015;22(2):112-6. doi: 10.3109/13506129.2015.1014548. Epub 2015 Jun 8. Amyloid. 2015. PMID: 26053104
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, Palladini G, Karlin L, Royer B, Huart A, Macro M, Morel P, Frenzel L, Touzeau C, Boyle E, Dorvaux V, Le Bras F, Lavergne D, Bridoux F, Jaccard A. Roussel M, et al. Among authors: lavergne d. Blood. 2020 Apr 30;135(18):1531-1540. doi: 10.1182/blood.2019004369. Blood. 2020. PMID: 32108228 Free article. Clinical Trial.
39 results